Medscape2d
Hematologist Dives Deep on MPN Research, Explains It Clearly
Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...
pharmaphorum1mon
Teva’s chronic myelogenous leukemia drug approved by US FDA
The drug’s effectiveness in chronic phase CML was demonstrated by a reduction in the percentage of cells expressing the Philadelphia chromosome genetic mutation found in most CML patients.
pharmaphorum10mon
ASCO: Novartis’ Scemblix aces first-line CML study
At the ASCO congress in Chicago today, the results of the ASC4FIRST trial of Scemblix (asciminib) in people recently diagnosed with Philadelphia chromosome-positive, chronic phase CML suggest the ...
Axios on MSN12d
Charlotte Mecklenburg Library leaders seek input on new, larger Sugar Creek Library
Charlotte Mecklenburg Library plans to build a new Sugar Creek Library branch that will be more than double the size of the ...
Medscape12d
Dose Escalation of Imatinib in Chronic-phase Chronic Myeloid Leukemia Patients
Table 1. Cytogenetic and molecular response rates of large clinical trials testing first-line high-dose imatinib in chronic-phase chronic myeloid leukemia. Study (year) Trial Response (%) Ref.
Hosted on MSN3mon
FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that does not require mealtime restrictions, to ...